Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.

  title={Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.},
  author={Peter Henriksson and Olof Edhag},
  journal={British Medical Journal (Clinical research ed.)},
  pages={413 - 415}
One hundred consecutive patients aged up to 75 with newly diagnosed cancer of the prostate suitable for hormonal treatment were included in a controlled study of the cardiovascular effects of oestrogen versus orchidectomy. In all cases pre-existing cardiovascular morbidity was excluded. Of the 100 patients, 91 were strictly randomised to receive either oestrogen (n = 47) or orchidectomy (n = 44) and 9 (6 given oestrogen, 3 orchidectomy) either chose their own treatment (five cases) or had it… 

Oestrogen dosage in prostatic cancer: the threshold effect?

It may be necessary to reduce plasma testosterone to midway between castrate and normal ranges in patients with hormone-sensitive prostatic carcinoma, and the effective dose of oestrogen may be reduced and the risk of thrombo-embolic complications minimised.

Oestrogen in the Treatment of Prostatic Carcinoma

Summary— The treatment of prostatic carcinoma with diethylstilboestrol (DES) and ethinyloestradiol (Lynoral) has become less popular since the introduction of new forms of treatment such as

Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer

Patients with prostatic cancer during long-term oestrogen treatment were found to have increased levels of factor VII, factor VIII:C and fibrinogen, and patients showed increased formation of thromboxane, which imply a hypercoaguable state and platelet activation.

Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population

  • J. Aro
  • Medicine
    The Prostate
  • 1991
It is concluded that intramuscular PEP monotherapy is associated with low cardiovascular mortality and with an all‐cause and prostatic cancer mortality equal to orchiectomy.

Challenges in the management of prostate cancer.

Combined therapy for total androgen ablation may become the new treatment standard for advanced prostatic cancer, pending further studies in the efficacy and cost-effectiveness of all available treatments.

Therapeutic options in treatment of advanced carcinoma of the prostate.

A review of the literature on the treatment of metastatic carcinoma of the prostate is presented to determine what should be recommended as standard therapy and total androgen blockade should be considered experimental.

Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.

It is shown that depot preparations of LHRH-analogues, both with and without pretreatment with CPA, are useful in the treatment of patients with advanced prostatic cancer.

Controversies in the management of advanced prostate cancer

  • C. Tyrrell
  • Medicine, Biology
    British Journal of Cancer
  • 1999
The author favours the view that CAB has an advantage over castration, and may be associated with a lower incidence of side-effects compared with the other non-steroidal anti-androgens and, in common with nilutamide, has the advantage of once-daily dosing.



Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

  • Medicine
    The New England journal of medicine
  • 1984
It is concluded that leuprolide offers an important alternative treatment that is therapeutically equivalent to and causes fewer side effects than DES for the initial systemic management of metastatic prostate cancer.

Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.

Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease, venous thromboembolism, cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment.

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

The 1.0-mg dose has been as effective as the 5.0‐mg dose in controlling the prostate cancer, but it does not seem to be associated with the excess risk of cardiovascular death.

Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma.

  • L. WallentinE. Varenhorst
  • Medicine, Biology
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 1981
The changes in plasma lipoprotein pattern created by high doses of estrogens are mainly thought to protect against the development of atherosclerosis, but the slight changes that take place after orchidectomy can hardly affect the incidence of cardiovascular disease.


Evidence is presented that significant improvement often occurs in the clinical condition of patients with far advanced cancer of the prostate after they have been subjected to castration and this work provides a new concept of prostatic carcinoma.

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate

It is demonstrated that a marked rise in acid phosphatase in serum is associated with the appearance or spread of roentgenologically demonstrable skeletal metastases and implies dissemination of the primary tumor and thus is of unfavorable prognostic significance.

Consequences of assessment and intervention among elderly people: a three year randomised controlled trial.

Subjects in the intervention group benefited from the regular visits and the increased distribution of aids and modifications to their homes to which these led, and probably also produced an important increase in confidence.